Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

C2174000

Cilazapril

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Cilazapril monohydrate

Sign Into View Organizational & Contract Pricing

Select a Size

50 MG
$164.00

$164.00

Check Cart for Availability
Request a Bulk Order
Notify Me

Get notified when this item is ready to ship via email.

All Photos(1)

Select a Size

Change View
50 MG
$164.00

About This Item

Empirical Formula (Hill Notation):
C22H31N3O5 · H2O
CAS Number:
92077-78-6
Molecular Weight:
435.51
MDL number:
MFCD01692810
UNSPSC Code:
41116107
NACRES:
NA.24

$164.00

Check Cart for Availability
Request a Bulk Order
Notify Me

Get notified when this item is ready to ship via email.

grade

pharmaceutical primary standard

API family

cilazapril

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

N21N(CCC[C@H]2C(=O)O)CCC[C@@H](C1=O)N[C@@H](CCc3ccccc3)C(=O)OCC.O

InChI

1S/C22H31N3O5.H2O/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26;/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28);1H2/t17-,18-,19-;/m0./s1

InChI key

JQRZBPFGBRIWSN-YOTVLOEGSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cilazapril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Izzet Hosgor et al.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 19(1), 101-105 (2008-01-09)
Impaired fibrinolysis is associated with thromboembolic complications in hypertensive patients. Cardiovascular morbidity/mortality rates have been reported high even after lowering the elevated blood pressure with antihypertensive drugs. We investigated the effects of clinically used dosages of cilazapril on the fibrinolytic
[The study of the effect of Cilazapril and valsartan on angiotensin 1 and angiotensin 2 receptors mRNA expression and myocardial interstitial collagen metabolism after myocardial infarction in rats].
Shi-shu Zhang et al.
Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue, 20(4), 240-241 (2008-04-19)
Leszek Tylicki et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 52(3), 486-493 (2008-04-22)
Agents inhibiting the renin-angiotensin-aldosterone (RAAS) system have an important role in slowing the progression of chronic kidney disease. We evaluated the hypothesis that the addition of an aldosterone receptor antagonist to an angiotensin-converting enzyme (ACE) inhibitor and angiotensin II type
Nikola Radović et al.
Croatian medical journal, 49(5), 600-607 (2008-10-18)
To investigate the effects of angiotensin-converting enzyme inhibitor (cilazapril) and angiotensin II type I receptor antagonist (losartan) on tubular and interstitial cell apoptosis and caspase-3 activity in rats with obstructive nephropathy after unilateral ureteral obstruction. Rats with unilateral obstructive nephropathy
Shih-Hsien Sung et al.
Journal of the Chinese Medical Association : JCMA, 71(5), 247-253 (2008-05-21)
Combined regimen may be superior to monotherapy in blood pressure (BP) control. Since BP control is critically related to cardiovascular mortality and morbidity in hypertensive patients, this study aimed to evaluate the efficacy and safety of a low-dose combined regimen
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service